"The U.S. Food and Drug Administration today approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children.
Neuroblastoma is a r"...
(carfilzomib) Intraveneous Injection
Kyprolis (carfilzomib) is an antineoplastic agent available for intravenous use only. Kyprolis is a sterile, white to off-white lyophilized powder and is available as a single-dose vial. Each vial of Kyprolis contains 60 mg of carfilzomib, 3000 mg sulfobutyl ether beta-cyclodextrin, 57.7 mg citric acid, and sodium hydroxide for pH adjustment (target pH 3.5).
Carfilzomib is a modified tetrapeptidyl epoxide, isolated as the crystalline free base. The chemical name for carfilzomib is (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran- 2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)- 4-phenylbutanamido)-4-methylpentanamide. Carfilzomib has the following structure:
Carfilzomib is a crystalline substance with a molecular weight of 719.9. The molecular formula is C40H57N5O7. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions.
Last reviewed on RxList: 9/15/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Kyprolis Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.